Ciltacabtagene autoleucel (original) (raw)
Ciltacabtagene autoleucel, sold under the brand name Carvykti, is a medication used to treat multiple myeloma. The most common adverse reactions include pyrexia, cytokine release syndrome, hypogammaglobulinemia, musculoskeletal pain, fatigue, infections, diarrhea, nausea, encephalopathy, headache, coagulopathy, constipation, and vomiting. Additional common side effects include neutropenia (low levels of neutrophils), lymphopenia and leucopenia (low levels of lymphocytes or other white blood cells), anemia (low levels of red blood cells), thrombocytopenia (low levels of blood platelets), hypotension (low blood pressure), pain of the muscles and bones, high level of liver enzymes, upper respiratory tract infection (nose and throat infection), diarrhea, hypokalemia (low level of potassium), h
| Property | Value |
|---|---|
| dbo:abstract | Ciltacabtagene autoleucel, sold under the brand name Carvykti, is a medication used to treat multiple myeloma. The most common adverse reactions include pyrexia, cytokine release syndrome, hypogammaglobulinemia, musculoskeletal pain, fatigue, infections, diarrhea, nausea, encephalopathy, headache, coagulopathy, constipation, and vomiting. Additional common side effects include neutropenia (low levels of neutrophils), lymphopenia and leucopenia (low levels of lymphocytes or other white blood cells), anemia (low levels of red blood cells), thrombocytopenia (low levels of blood platelets), hypotension (low blood pressure), pain of the muscles and bones, high level of liver enzymes, upper respiratory tract infection (nose and throat infection), diarrhea, hypokalemia (low level of potassium), hypocalcemia (low levels of calcium), hypophosphatemia (low levels of phosphate in the blood), nausea, headache, cough, tachycardia (rapid heartbeat), encephalopathy (a brain disorder), edema (fluid retention), decreased appetite, chills, fever, tiredness, as well as cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure). Ciltacabtagene autoleucel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy. Each dose is customized using the recipient's own T-cells, which are collected and genetically modified, and infused back into the recipient. Ciltacabtagene autoleucel was approved for medical use in the United States in February 2022, and in the European Union in May 2022. (en) |
| dbo:alternativeName | Carvykti (en) |
| dbo:drugbank | DB16738 |
| dbo:fdaUniiCode | 0L1F17908Q |
| dbo:kegg | D12315 |
| dbo:wikiPageExternalLink | https://druginfo.nlm.nih.gov/drugportal/name/ciltacabtagene%20autoleucel |
| dbo:wikiPageID | 70329684 (xsd:integer) |
| dbo:wikiPageLength | 12212 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1124404028 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Priority_review dbc:Drugs_that_are_a_gene_therapy dbr:Orphan_drug dbr:Multiple_myeloma dbr:Committee_for_Medicinal_Products_for_Human_Use dbc:Orphan_drugs dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbr:Breakthrough_therapy dbc:Antineoplastic_drugs dbc:Gene_therapy dbc:Breakthrough_therapy dbr:Medication dbr:Intravenous dbr:Indicated |
| dbp:atcPrefix | None (en) |
| dbp:dailymedid | Ciltacabtagene_autoleucel (en) |
| dbp:drugbank | DB16738 (en) |
| dbp:kegg | D12315 (en) |
| dbp:legalEu | Rx-only (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:routesOfAdministration | dbr:Intravenous |
| dbp:synonyms | JNJ-68284528 (en) |
| dbp:tradename | Carvykti (en) |
| dbp:unii | 0 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Chemotherapeutic_agents dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_American_English dbt:Use_dmy_dates |
| dct:subject | dbc:Drugs_that_are_a_gene_therapy dbc:Orphan_drugs dbc:Antineoplastic_drugs dbc:Gene_therapy dbc:Breakthrough_therapy |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Ciltacabtagene autoleucel, sold under the brand name Carvykti, is a medication used to treat multiple myeloma. The most common adverse reactions include pyrexia, cytokine release syndrome, hypogammaglobulinemia, musculoskeletal pain, fatigue, infections, diarrhea, nausea, encephalopathy, headache, coagulopathy, constipation, and vomiting. Additional common side effects include neutropenia (low levels of neutrophils), lymphopenia and leucopenia (low levels of lymphocytes or other white blood cells), anemia (low levels of red blood cells), thrombocytopenia (low levels of blood platelets), hypotension (low blood pressure), pain of the muscles and bones, high level of liver enzymes, upper respiratory tract infection (nose and throat infection), diarrhea, hypokalemia (low level of potassium), h (en) |
| rdfs:label | Ciltacabtagene autoleucel (en) |
| owl:sameAs | wikidata:Ciltacabtagene autoleucel https://global.dbpedia.org/id/GRu8F |
| prov:wasDerivedFrom | wikipedia-en:Ciltacabtagene_autoleucel?oldid=1124404028&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Ciltacabtagene_autoleucel |
| is dbo:wikiPageRedirects of | dbr:Carvykti |
| is dbo:wikiPageWikiLink of | dbr:List_of_gene_therapies dbr:Multiple_myeloma dbr:Carvykti dbr:CAR_T_cell |
| is foaf:primaryTopic of | wikipedia-en:Ciltacabtagene_autoleucel |